In the Media

Executive interview – InMed Pharmaceuticals
In this interview, Eric Adams, chief executive officer of InMed Pharmaceuticals provides an overview of InMed’s differentiated biosynthesis platform and its therapeutic pipeline of cannabinoids....
Source: Edison Group
Producing Cannabinoids Without the Plant!
A biosynthesis platform technology Cannabinoids are closely related compounds that are the active constituents of the cannabis plant. While there are over 100 different cannabinoids, the...
Source: BTV
Reimagining Medicine? Novartis Wraps Pharma’s First Big Global Pot Deal
In a watershed moment for medical cannabis advocates in the United States, Swiss giant Novartis’ $NVS Sandoz AG unit has tied up with Canadian medical...
Source: Endpoints News
The Promise of Cannabinoids to Treat Pain
The focus of treating pain over the last decade has led to the emergence of a number of opioid drugs. Since their introduction, this method...
Source: Money Inc
Looking Through the Telescope Onto the Horizon: InMed Pharmaceuticals
Nearly every week, there is another cannabis-themed headline such as “New Study Says 97% of Elderly Patients Say Cannabis Makes Them Feel Better, Decrease Prescription...
Source: Terpenes and Testing Magazine
How Biosynthesis of Cannabinoids Could Impact the Cannabis Industry
A highly disruptive technology that I have discussed over the past few years appears to be gaining traction. Biosynthesis, an alternative, natural method of producing...
Source: New Cannabis Ventures